Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Non-Current Deffered Revenue (2016 - 2025)

Traws Pharma's Non-Current Deffered Revenue history spans 14 years, with the latest figure at $2.5 million for Q1 2025.

  • Quarterly results put Non-Current Deffered Revenue at $2.5 million for Q1 2025, down 8.3% from a year ago — trailing twelve months through Mar 2025 was $2.5 million (down 8.3% YoY), and the annual figure for FY2024 was $2.6 million, down 8.1%.
  • Non-Current Deffered Revenue for Q1 2025 was $2.5 million at Traws Pharma, down from $2.6 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $3.4 million in Q1 2021 to a low of $2.5 million in Q1 2025.
  • The 5-year median for Non-Current Deffered Revenue is $3.0 million (2023), against an average of $3.0 million.
  • The sharpest move saw Non-Current Deffered Revenue fell 6.21% in 2021, then decreased 8.3% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $3.2 million in 2021, then fell by 6.97% to $3.0 million in 2022, then fell by 7.49% to $2.8 million in 2023, then dropped by 8.1% to $2.6 million in 2024, then fell by 2.22% to $2.5 million in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $2.5 million, $2.6 million, and $2.6 million for Q1 2025, Q4 2024, and Q3 2024 respectively.